NICE published appeal decisions on 20 March 2026 upholding several grounds raised by Eisai and Eli Lilly against the June 2025 rejection of lecanemab and donanemab, including the way the appraisal committee assessed carer utility values. In the donanemab decision, the panel also found the committee had not considered unpaid care costs through a non-reference case scenario analysis, and recorded the argument that the carer values used were "grossly under-estimated" compared with vignette-based estimates put forward by both the evidence assessment group and the company. The appraisals were remitted for reconsideration of those specific points. A third draft guidance consultation was published on 31 March 2026 and closed on 28 April 2026. The committee meeting was listed for 10 June 2026; The Pharmaceutical Journal reported that a fourth committee meeting was held on 8 July 2026, and that on 29 July 2026 Lilly said it was in dialogue with NICE while Eisai confirmed commercial discussions with NICE and NHS England. NICE's project page still gives the expected publication date as to be confirmed.
The dispute is not about amyloid. It is about a number in a spreadsheet: how much a carer's own quality of life is assumed to fall as the person they care for moves from mild cognitive impairment through to severe dementia, and whether the hours of dressing, supervising and driving that sit behind that fall are counted as costs at all. NICE's reference case uses the EQ-5D questionnaire, and the evidence group preferred patient EQ-5D values from the GERAS study, completed by carers as proxies, over the company's pooled meta-analysis values, which it said fell outside the reference case because they were not drawn from a representative UK sample.
The panels did not accept everything. On one donanemab ground they agreed that NICE's manual treats the health of a person as covering patient and carer alike, and that EQ-5D remains the preferred method, with departures requiring the company to demonstrate the instrument is not appropriate; that point was dismissed. Infusion costs were the other live issue: the appeal decision records Lilly's estimate of £207.39 against NHS England's figure of about £500. Both drugs are licensed in Great Britain, lecanemab in August 2024 and donanemab in October 2024, and NICE has said no three times, most recently in final draft guidance on 19 June 2025, on the grounds that trial benefits were small relative to the cost of buying and delivering the drugs.
An appeal panel rules on process and reasonableness, not on whether a medicine works. Nothing in the March 2026 decisions changes the trial results, the rate of amyloid-related imaging abnormalities, or who would be eligible. Michelle Dyson, chief executive of the Alzheimer's Society, said the decision to look again at the impact on unpaid carers was welcome, adding that carers are "too often pushed to breaking point". The committee's revised conclusions have not been published.